Vertex Pharmaceuticals saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal challenges ...

Ratings for Vertex Pharmaceuticals VRTX were provided by 18 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their ...

Vertex Pharmaceuticals has a 1 year low of $377.85 and a 1 year high of $519.88. The stock has a fifty day moving average of $484.84 and a two-hundred day moving average of $464.28.

The Motley Fool has positions in and recommends AbbVie, Amgen, Pfizer, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Fed Chairman Jerome Powell Warns Trump's Tariffs Could ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them. The 10 stocks that ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX).Compared to the S&P 500 index, which is down about ...

Analysts' ratings for Vertex Pharmaceuticals VRTX over the last quarter vary from bullish to bearish, as provided by 17 analysts. The table below summarizes their recent ratings, showcasing the ...

In other Vertex Pharmaceuticals news, EVP David Altshuler sold 3,231 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $500.00 ...